83 FR 58263 - Center for Scientific Review; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 223 (November 19, 2018)

Page Range		58263-58263
FR Document		2018-25196

Federal Register, Volume 83 Issue 223 (Monday, November 19, 2018)

[Federal Register Volume 83, Number 223 (Monday, November 19, 2018)]
[Notices]
[Page 58263]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-25196]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel, PAR18-822: Approaches for Understanding Disease Mechanisms 
and Improving Outcomes in TB Meningitis (TBM).
    Date: December 12, 2018.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Virtual Meeting).
    Contact Person: Guangyong Ji, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 3211, MSC 7808, Bethesda, MD 20892, 301-435-
1146, jig@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: November 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-25196 Filed 11-16-18; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 223 / Monday, November 19, 2018 / Notices 58263

Intellectual Property presumed to contain business DEPARTMENT OF HEALTH AND
confidential information and any release HUMAN SERVICES
E–133–2016: FLT3-Specific Chimeric
of information from these license
Antigen Receptors and Methods Using National Institutes of Health
applications will be made only as
Same
required and upon a request under the
1. US Provisional Patent Application Freedom of Information Act, 5 U.S.C. National Heart, Lung, and Blood
62/342,394, filed May 27, 2016 (E–133– 552. Institute; Notice of Meetings
2016–0–US–01); Pursuant to section 10(d) of the
Dated: November 8, 2018.
2. International Patent Application
Richard U. Rodriguez, Federal Advisory Committee Act, as
PCT/US2017/034,691, filed May 26,
Associate Director, Technology Transfer amended, notice is hereby given of the
2017 (E–133–2016–0–PCT–02)
The patent rights in these inventions Center, National Cancer Institute. following meetings.
[FR Doc. 2018–25197 Filed 11–16–18; 8:45 am] The meetings will be closed to the
have been assigned and/or exclusively
public in accordance with the
licensed to the government of the BILLING CODE 4140–01–P
provisions set forth in sections
United States of America.
The prospective exclusive license 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
territory may be worldwide, and the DEPARTMENT OF HEALTH AND as amended. The grant applications and
fields of use may be limited to the HUMAN SERVICES the discussions could disclose
following: confidential trade secrets or commercial
‘‘The development of a mono- or National Institutes of Health property such as patentable material,
multi-specific FMS-like tyrosine kinase and personal information concerning
Center for Scientific Review; Notice of individuals associated with the grant
3 (FLT3; also known as CD135) chimeric
Closed Meeting applications, the disclosure of which
antigen receptor (CAR)-based
immunotherapy using autologous or Pursuant to section 10(d) of the would constitute a clearly unwarranted
allogenic human lymphocytes (T cells Federal Advisory Committee Act, as invasion of personal privacy.
or NK cells) transduced with lentiviral amended, notice is hereby given of the Name of Committee: National Heart, Lung,
vectors, wherein the viral transduction following meeting. and Blood Institute Special Emphasis Panel;
leads to the expression of a CAR that The meeting will be closed to the Catalyzing Innovation in Trial Design.
targets FLT3 (comprised of the FLT3- public in accordance with the Date: December 6, 2018.
binding domain referenced as NC7 in provisions set forth in sections Time: 10:00 a.m. to 10:30 a.m.
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Agenda: To review and evaluate grant
the invention as well as an intracellular applications.
signaling domain), for the prophylaxis as amended. The grant applications and Place: National Institutes of Health, 6701
or treatment of FLT3-expressing the discussions could disclose Rockledge Drive, Room 7180, Bethesda, MD
cancers.’’ confidential trade secrets or commercial 20892 (Telephone Conference Call).
This technology discloses a CAR property such as patentable material, Contact Person: Tony L. Creazzo, Ph.D.,
vector that targets FLT3 comprised of an and personal information concerning Scientific Review Officer, Office of Scientific
anti-FLT3 antibody known as NC7, and individuals associated with the grant Review, National Heart, Lung, and Blood
an intracellular signaling domain. FLT3 applications, the disclosure of which Institute, National Institutes of Health, 6701
(CD135) is a cytokine receptor expressed would constitute a clearly unwarranted Rockledge Drive, Room 7180, Bethesda, MD
invasion of personal privacy. 20892, 301–827–7913, creazzotl@
on hematopoietic progenitor cells, and
mail.nih.gov.
is one of the most frequently mutated Name of Committee: Center for Scientific Name of Committee: National Heart, Lung,
genes in acute myeloid leukemia (AML) Review Special Emphasis Panel, PAR18–822: and Blood Institute Special Emphasis Panel;
and infant acute lymphoblastic Approaches for Understanding Disease Catalyzing Innovation in Trial Design
leukemia (ALL). FLT3 mutation leads to Mechanisms and Improving Outcomes in TB Resource Access.
increased cell surface expression and Meningitis (TBM). Date: December 6, 2018.
therefore on leukemic cells, which Date: December 12, 2018. Time: 10:30 a.m. to 12:00 p.m.
makes it an attractive candidate for Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant
Agenda: To review and evaluate grant applications.
cellular therapies such as CAR–T.
applications. Place: National Institutes of Health, 6701
This Notice is made in accordance
Place: National Institutes of Health, 6701 Rockledge Drive, Room 7180, Bethesda, MD
with 35 U.S.C. 209 and 37 CFR part 404. Rockledge Drive, Bethesda, MD 20892,
The prospective exclusive license will 20892 (Telephone Conference Call).
(Virtual Meeting). Contact Person: Tony L. Creazzo, Ph.D.,
be royalty bearing, and the prospective Contact Person: Guangyong Ji, Ph.D., Scientific Review Officer, Office of Scientific
exclusive license may be granted unless Scientific Review Officer, Center for Review, National Heart, Lung, and Blood
within fifteen (15) days from the date of Scientific Review, National Institutes of Institute, National Institutes of Health, 6701
this published Notice, the National Health, 6701 Rockledge Drive, Room 3211, Rockledge Drive, Room 7180, Bethesda, MD
Cancer Institute receives written MSC 7808, Bethesda, MD 20892, 301–435– 20892, 301–827–7913, creazzotl@
evidence and argument that establishes 1146, jig@csr.nih.gov. mail.nih.gov.
that the grant of the license would not (Catalogue of Federal Domestic Assistance Name of Committee: National Heart, Lung,
be consistent with the requirements of Program Nos. 93.306, Comparative Medicine; and Blood Institute Special Emphasis Panel;
93.333, Clinical Research, 93.306, 93.333, Integrative Computational Biology for
35 U.S.C. 209 and 37 CFR part 404.
93.337, 93.393–93.396, 93.837–93.844, Analysis of NHLBI TOPMed Data.
In response to this Notice, the public 93.846–93.878, 93.892, 93.893, National Date: December 7, 2018.
khammond on DSK30JT082PROD with NOTICES

may file comments or objections. Institutes of Health, HHS)
Comments and objections, other than Time: 8:00 a.m. to 5:00 p.m.
Dated: November 14, 2018. Agenda: To review and evaluate grant
those in the form of a license applications.
application, will not be treated Natasha M. Copeland,
Place: Embassy Suites at the Chevy Chase
confidentially, and may be made Program Analyst, Office of Federal Advisory
Pavilion, 4300 Military Road NW,
publicly available. Committee Policy.
Washington, DC 20015.
License applications submitted in [FR Doc. 2018–25196 Filed 11–16–18; 8:45 am] Contact Person: Susan Wohler Sunnarborg,
response to this Notice will be BILLING CODE 4140–01–P Ph.D., Scientific Review Officer, Office of

VerDate Sep<11>2014 17:20 Nov 16, 2018 Jkt 247001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\19NON1.SGM 19NON1

Document Created: 2018-11-17 02:46:27
Document Modified: 2018-11-17 02:46:27

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		December 12, 2018.
FR Citation		83 FR 58263

83 FR 58263 - Center for Scientific Review; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 223 (November 19, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health